139 related articles for article (PubMed ID: 12770819)
1. Understanding HTLV-I protease.
Shuker SB; Mariani VL; Herger BE; Dennison KJ
Chem Biol; 2003 May; 10(5):373-80. PubMed ID: 12770819
[No Abstract] [Full Text] [Related]
2. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J
J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858
[TBL] [Abstract][Full Text] [Related]
3. Substrates and inhibitors of human T-cell leukemia virus type I protease.
Ding YS; Rich DH; Ikeda RA
Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
[TBL] [Abstract][Full Text] [Related]
4. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
Tözsér J; Weber IT
Curr Pharm Des; 2007; 13(12):1285-94. PubMed ID: 17504236
[TBL] [Abstract][Full Text] [Related]
5. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.
Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I
Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292
[TBL] [Abstract][Full Text] [Related]
6. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding.
Daenke S; Schramm HJ; Bangham CR
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2233-9. PubMed ID: 8077922
[TBL] [Abstract][Full Text] [Related]
7. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate.
Kumada HO; Nguyen JT; Kakizawa T; Hidaka K; Kimura T; Hayashi Y; Kiso Y
J Pept Sci; 2011 Aug; 17(8):569-75. PubMed ID: 21574213
[TBL] [Abstract][Full Text] [Related]
8. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.
Kuhnert M; Blum A; Steuber H; Diederich WE
J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468
[TBL] [Abstract][Full Text] [Related]
9. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
Maegawa H; Kimura T; Arii Y; Matsui Y; Kasai S; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2004 Dec; 14(23):5925-9. PubMed ID: 15501070
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR.
Selvaraj C; Singh P; Singh SK
J Mol Recognit; 2014 Dec; 27(12):696-706. PubMed ID: 25319617
[TBL] [Abstract][Full Text] [Related]
11. C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.
Kádas J; Boross P; Weber IT; Bagossi P; Matúz K; Tözsér J
Biochem J; 2008 Dec; 416(3):357-64. PubMed ID: 18636969
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
Li M; Laco GS; Jaskolski M; Rozycki J; Alexandratos J; Wlodawer A; Gustchina A
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18332-7. PubMed ID: 16352712
[TBL] [Abstract][Full Text] [Related]
13. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase.
Louis JM; Oroszlan S; Tözsér J
J Biol Chem; 1999 Mar; 274(10):6660-6. PubMed ID: 10037763
[TBL] [Abstract][Full Text] [Related]
14. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.
Sperka T; Miklóssy G; Tie Y; Bagossi P; Zahuczky G; Boross P; Matúz K; Harrison RW; Weber IT; Tözsér J
J Gen Virol; 2007 Jul; 88(Pt 7):2052-2063. PubMed ID: 17554040
[TBL] [Abstract][Full Text] [Related]
15. Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.
Awahara C; Tatsumi T; Furuta S; Shinjoh G; Konno H; Nosaka K; Kobayashi K; Hattori Y; Akaji K
Bioorg Med Chem; 2014 Apr; 22(8):2482-8. PubMed ID: 24680060
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
17. Human T-cell leukemia virus type 1 protease protein expressed in Escherichia coli possesses aspartic proteinase activity.
Saiga A; Tanaka T; Orita S; Sato A; Sato S; Hachisu T; Abe K; Kimura Y; Kondo Y; Fujiwara T
Arch Virol; 1993; 128(3-4):195-210. PubMed ID: 8435041
[TBL] [Abstract][Full Text] [Related]
18. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
19. p15gag proteinase of myeloblastosis associated virus: specificity studies with substrate based inhibitors.
Strop P; Pavlícková L; Stys D; Soucek M; Urban J; Hrusková O; Kaprálek F; Jecmen P; Sedlácek J; Kostka V
Adv Exp Med Biol; 1991; 306():519-23. PubMed ID: 1812752
[No Abstract] [Full Text] [Related]
20. The 10 C-terminal residues of HTLV-I protease are not necessary for enzymatic activity.
Herger BE; Mariani VL; Dennison K; Shuker SB
Biochem Biophys Res Commun; 2004 Aug; 320(4):1306-8. PubMed ID: 15303275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
